Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mödling – page 27

863 clinical trials in Mödling, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mödling at a glance
863
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

863 trials in Mödling

Open in trial search

Pre-eclampsia

Recruiting

Study on Aspirin for Preventing Preeclampsia in Twin Pregnancies

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Ewing's sarcoma

Recruiting

Study on Ewing Sarcoma Treatment with Vinorelbine and Drug Combination for Patients with Primary and Disseminated Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:GPOH gGmbH

Study of ONC201 for Patients with Newly Diagnosed H3 K27M-mutant Diffuse Glioma After Radiotherapy

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dordaviprone
  • Sponsor:Chimerix Inc.

Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Marstacimab
  • Sponsor:Pfizer Inc.

Pneumonia

Recruiting

Study of Trimodulin for Adults Hospitalized with Severe Community-Acquired Pneumonia

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Trimodulin (Human Igm, Iga, Igg Solution)
  • Sponsor:Biotest GmbH & Co. KGaA

Study on Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Servier Affaires Medicales

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on Desflurane, Sevoflurane, and Propofol for Postoperative Delirium in Elderly Patients Undergoing Major Abdominal Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Desflurane
  • Sponsor:Medical University Of Vienna

Study on Long-Term Safety of Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mödling

What the registry says about research in the country

01 Diabetes & Cardiovascular Health

Clinical research focusing on Type 2 Diabetes Mellitus patients, exploring innovative approaches to prevent heart disease. The trials evaluate the effectiveness of intensive treatment using RAS-antagonists and beta-blockers compared to standard therapy.

  • Heart Disease Prevention
  • Diabetes Management
  • Cardiac Event Reduction

Studies utilize specialized biomarkers like NT-proBNP to guide treatment strategies and reduce hospitalization rates.

02 Stroke Prevention Research

Investigating advanced treatments for ischemic stroke prevention, with particular focus on patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Post-Stroke Care
  • Blood Clot Prevention
  • Antiplatelet Therapy

The research evaluates the efficacy of asundexian, an oral FXIa inhibitor, in combination with standard antiplatelet therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.